NRXP
NRx Pharmaceuticals, Inc.
Biotechnology
Market Cap$85M
5Y Perf.-97.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
NRXP vs INMB
Revenue, margins, valuation, and 5-year total return — side by side.
INMB
INmune Bio, Inc.
Biotechnology
Market Cap$38M
5Y Perf.-74.9%
NRXP vs INMB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NRXP | INMB |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $85M | $38M |
| Revenue (TTM) | $242K | $0.00 |
| Net Income (TTM) | $-38M | $-42M |
| Gross Margin | 59.5% | 100.0% |
| Operating Margin | -63.0% | -617.4% |
| Total Debt | $631K | $1M |
| Cash & Equiv. | $8M | $25M |
NRXP vs INMB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NRXP
INMB
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| NRx Pharmaceuticals… (NRXP) | 100 | 2.8 | -97.2% |
| INmune Bio, Inc. (INMB) | 100 | 25.1 | -74.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NRXP vs INMB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NRXP leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. INmune Bio, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
NRXP
NRx Pharmaceuticals, Inc.
The Income Pick
NRXP carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.91
- EPS growth 43.9%
- Lower volatility, beta 1.91, current ratio 0.31x
Best for: income & stability and growth exposure
INMB
INmune Bio, Inc.
The Long-Run Compounder
INMB is the clearest fit if your priority is long-term compounding.
- -82.1% 10Y total return vs NRXP's -96.8%
- 257.1% revenue growth vs NRXP's 101.1%
- -128.8% ROA vs NRXP's -489.9%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | INMB | 257.1% revenue growth vs NRXP's 101.1% |
| Quality / Margins | NRXP | -157.3% margin vs INMB's -918.7% |
| Stability / Safety | NRXP | Beta 1.91 vs INMB's 2.45 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NRXP | +55.3% vs INMB's -80.0% |
| Efficiency (ROA) | INMB | -128.8% ROA vs NRXP's -489.9% |
NRXP vs INMB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
NRXP vs INMB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNRXPLAGGINGINMB
INMBINmune Bio, Inc.
0leads
NRXPNRx Pharmaceuticals, …
4leads
6 Total Categories
CATEGORYLEADERvs INMBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NRXP3/5
Valuation MetricsMultiples, price ratios, and targets
NRXP2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
NRXP4/6
Risk & VolatilityBeta, volatility, and downside exposure
NRXP2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NRXP leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
NRXP and INMB operate at a comparable scale, with $242,000 and $0 in trailing revenue. NRXP is the more profitable business, keeping -157.3% of every revenue dollar as net income compared to INMB's -918.7%.
| Metric | NRXPNRx Pharmaceutica… | INMBINmune Bio, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $242,000 | $0 |
| EBITDAEarnings before interest/tax | -$31M | -$27M |
| Net IncomeAfter-tax profit | -$38M | -$42M |
| Free Cash FlowCash after capex | -$12M | -$21M |
| Gross MarginGross profit ÷ Revenue | +59.5% | +100.0% |
| Operating MarginEBIT ÷ Revenue | -63.0% | -617.4% |
| Net MarginNet income ÷ Revenue | -157.3% | -918.7% |
| FCF MarginFCF ÷ Revenue | -49.0% | -472.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -80.0% | +53.5% |
NRXP leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
NRXP leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | NRXPNRx Pharmaceutica… | INMBINmune Bio, Inc. |
|---|---|---|
| Market CapShares × price | $85M | $38M |
| Enterprise ValueMkt cap + debt − cash | $78M | $14M |
| Trailing P/EPrice ÷ TTM EPS | -2.28x | -0.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 69.15x | 760.34x |
| Price / BookPrice ÷ Book value/share | — | 1.62x |
| Price / FCFMarket cap ÷ FCF | — | — |
NRXP leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — NRXP and INMB each lead in 2 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), NRXP scores 5/9 vs INMB's 3/9, reflecting solid financial health.
| Metric | NRXPNRx Pharmaceutica… | INMBINmune Bio, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | — | -170.9% |
| ROA (TTM)Return on assets | -4.9% | -128.8% |
| ROICReturn on invested capital | — | -4.1% |
| ROCEReturn on capital employed | — | -109.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 |
| Debt / EquityFinancial leverage | — | 0.04x |
| Net DebtTotal debt minus cash | -$7M | -$24M |
| Cash & Equiv.Liquid assets | $8M | $25M |
| Total DebtShort + long-term debt | $631,000 | $1M |
| Interest CoverageEBIT ÷ Interest expense | -24.18x | — |
Evenly matched — NRXP and INMB each lead in 2 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
NRXP leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INMB five years ago would be worth $1,338 today (with dividends reinvested), compared to $92 for NRXP. Over the past 12 months, NRXP leads with a +55.3% total return vs INMB's -80.0%. The 3-year compound annual growth rate (CAGR) favors NRXP at -21.0% vs INMB's -44.5% — a key indicator of consistent wealth creation.
| Metric | NRXPNRx Pharmaceutica… | INMBINmune Bio, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +16.8% | -7.1% |
| 1-Year ReturnPast 12 months | +55.3% | -80.0% |
| 3-Year ReturnCumulative with dividends | -50.6% | -82.9% |
| 5-Year ReturnCumulative with dividends | -99.1% | -86.6% |
| 10-Year ReturnCumulative with dividends | -96.8% | -82.1% |
| CAGR (3Y)Annualised 3-year return | -21.0% | -44.5% |
NRXP leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
NRXP leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NRXP is the less volatile stock with a 1.91 beta — it tends to amplify market swings less than INMB's 2.45 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NRXP currently trades 79.7% from its 52-week high vs INMB's 12.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NRXPNRx Pharmaceutica… | INMBINmune Bio, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.91x | 2.45x |
| 52-Week HighHighest price in past year | $3.84 | $11.64 |
| 52-Week LowLowest price in past year | $1.62 | $1.09 |
| % of 52W HighCurrent price vs 52-week peak | +79.7% | +12.3% |
| RSI (14)Momentum oscillator 0–100 | 64.7 | 59.2 |
| Avg Volume (50D)Average daily shares traded | 913K | 384K |
NRXP leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | NRXPNRx Pharmaceutica… | INMBINmune Bio, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NRXP leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallNRx Pharmaceuticals, Inc. (NRXP)Leads 4 of 6 categories
Loading custom metrics...
NRXP vs INMB: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — NRXP or INMB?
Over the past 5 years, INmune Bio, Inc.
(INMB) delivered a total return of -86. 6%, compared to -99. 1% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: INMB returned -82. 1% versus NRXP's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — NRXP or INMB?
By beta (market sensitivity over 5 years), NRx Pharmaceuticals, Inc.
(NRXP) is the lower-risk stock at 1. 91β versus INmune Bio, Inc. 's 2. 45β — meaning INMB is approximately 28% more volatile than NRXP relative to the S&P 500.
03Which is growing faster — NRXP or INMB?
On earnings-per-share growth, the picture is similar: NRx Pharmaceuticals, Inc.
grew EPS 43. 9% year-over-year, compared to 11. 8% for INmune Bio, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — NRXP or INMB?
NRx Pharmaceuticals, Inc.
(NRXP) is the more profitable company, earning -23. 4% net margin versus -918. 7% for INmune Bio, Inc. — meaning it keeps -23. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NRXP leads at -1324. 4% versus -617. 4% for INMB. At the gross margin level — before operating expenses — INMB leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — NRXP or INMB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is NRXP or INMB better for a retirement portfolio?
For long-horizon retirement investors, NRx Pharmaceuticals, Inc.
(NRXP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. INmune Bio, Inc. (INMB) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NRXP: -96. 8%, INMB: -82. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between NRXP and INMB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NRXP is a small-cap quality compounder stock; INMB is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.